Lumira Ventures Hits First Close on US$200M Fund V to Champion North American Healthcare Innovation
TL;DR
Lumira Ventures, Canada's largest dedicated life sciences venture capital firm, has announced the first closing of Lumira Ventures V, LP — its fifth flagship fund, targeting US$200 million (C$275 million). The close comes alongside a planned leadership succession, with co-founder Gerry Brunk stepping up to Managing Partner as Peter van der Velden transitions to Executive Chairman. The fund has already deployed capital: a US$52 million Series B into a pre-commercial-stage medical device company. With more than 25 exits and US$100 billion in cumulative portfolio revenue over its history, Lumira is arguably the most credentialed healthcare-focused VC franchise in Canada, and Fund V signals that the firm is betting this is one of the most attractive moments in decades to deploy fresh capital into life sciences.
Key Takeaways
Leadership succession executed while the business is winning. Transitioning a founding GP to Executive Chairman while the firm still has strong momentum is the textbook right way to manage generational continuity. Brunk's elevation to Managing Partner — alongside the promotion of Isabelle Harris to Associate — signals a deliberate next-generation platform build rather than a reactive one. This kind of structured succession is rare in Canadian VC and materially de-risks the LP proposition.
Deploying into secondary North American markets is a genuine edge. Lumira explicitly targets biotech and medtech founders in markets "historically underserved by traditional coastal venture capital firms" — meaning beyond Boston, San Francisco, and New York. This is a sharper thesis than most healthcare generalists operate with, and the track record supports it: 40+ regulatory approvals and 15 million patients touched globally suggest the companies Lumira backs are getting to market, not just getting funded.
The macro case for healthcare VC is unusually strong right now. Brunk's investor letter argument is worth taking seriously: capital selectivity has increased (favoring specialist managers), AI is accelerating scientific productivity, healthcare systems face cost-reduction pressure that favors innovative solutions, and large-cap strategics are actively rebuilding product pipelines through M&A. That is a genuine convergence of tailwinds for a disciplined healthcare operator-investor.
Since 2024 alone, Lumira has delivered seven exits worth over US$8 billion. That's not a firm needing to prove itself — it's a firm raising its next fund from a position of realized strength. Follow-on capital raised by portfolio companies exceeds US$1.6 billion and seven FDA approvals have been secured in the same period. These are auditable, concrete performance markers, not aspirational claims.
Fund Overview
Fund Name: Lumira Ventures V, LP
Fund Size (Target): US$200M (C$275M)
Stage: Multi-stage (early to growth-stage healthcare)
Check Size: Not disclosed; first investment was US$52M Series B co-lead
Geography: North America, with emphasis on secondary markets beyond the traditional coastal hubs
Focus: Biotechnology and medical technology — both biotech drug development and medical devices/diagnostics
Key LPs: Northleaf Capital Partners (anchor, returning), Fonds de solidarité FTQ (LP since firm founding), plus institutional investors, strategic LPs, and family offices
Why This Fund Matters
Canadian life sciences venture capital has historically punched below its weight relative to the country's scientific output. Canada produces world-class research from institutions like the University of Toronto, McGill, UBC, and University of Alberta, yet the majority of companies born in those labs have historically been forced to relocate south to access growth capital. Lumira was founded precisely to address that structural gap, and Fund V represents their largest-ever flagship vehicle — a meaningful statement about what's now financeable from a Canadian platform.
The fund's emphasis on "secondary North American ecosystems" is also worth unpacking. The implication is that Lumira isn't just writing checks into Toronto and Montreal — it's actively scouting in markets like Calgary, Halifax, and secondary US cities where deep science exists but coastal VC attention is thin. For founders in those markets, Lumira often represents the highest-quality institutional lead available. That market positioning creates deal flow others can't access.
Perhaps most importantly, Fund V arrives at a specific inflection point in healthcare where the risk-reward calculus has materially shifted in favor of experienced specialists. Generalist funds that piled into healthcare during 2020-2021 are largely retreating from the sector as valuations corrected and deal complexity became apparent. The specialist managers who stayed disciplined through that cycle — including Lumira — are now operating in a market with better pricing, less crowding, and a clear runway to exits as Big Pharma M&A accelerates to replenish pipelines depleted by patent cliffs. Lumira's seven recent exits since 2024 at over US$8 billion in aggregate value suggests this pipeline is very real.
One nuance worth flagging: the fund is seventh overall for the firm, counting three strategic funds alongside the five flagship vehicles. This multi-layered structure — strategic funds likely co-investing alongside or bridging portfolio companies — gives Lumira tactical flexibility that single-fund managers don't have. In healthcare, where companies sometimes need bridge capital between financing rounds, that flexibility is a genuine competitive advantage.
The Team
Gerry Brunk, now Managing Partner, co-founded Lumira and has been the operational and strategic engine behind the firm's build-out across Toronto, Montreal, Vancouver, and Boston. His elevation formalizes what was already the firm's day-to-day operating reality. Peter van der Velden, transitioning to Executive Chairman, remains the firm's longest-serving investor and will continue engaging with Canadian stakeholders and LPs — a sensible division of labor that preserves institutional relationships while giving Brunk full operational authority.
Isabelle Harris, promoted to Associate and based in Toronto, covers both biotech and medtech sourcing and evaluation. Her promotion is part of the deliberate next-generation build the firm is executing. Lumira's investment team spans all four offices, giving it coverage across Canada's major academic and research clusters as well as the Boston life sciences corridor — arguably the world's most productive biotech hub. That geographic footprint is genuinely differentiated for a Canadian-headquartered manager.
Early Portfolio
Fund V's first investment has been completed — a US$52 million Series B financing for an undisclosed pre-commercial-stage medical device company. The scale of the check relative to the fund size (roughly 26% of the total target deployed in the first round) suggests Lumira is willing to take meaningful concentrated positions in companies it has high conviction on, rather than spreading thin across a large portfolio. The prior Lumira flagship funds have backed companies that generated over US$100 billion in cumulative revenue across the firm's history, including multiple IPOs and strategic acquisitions with well-known healthcare strategics.
What This Means for Founders
If you are building a biotech or medtech company in a North American secondary market — anywhere from Calgary to the Research Triangle to the Upper Midwest — Lumira is one of the few institutional leads that will fly to your city, engage deeply with your science, and write a meaningful check without requiring you to relocate. That matters enormously for founders who have built academic and clinical networks in their home cities and don't want to abandon them. Lumira's board-level engagement model and hands-on commercialization support (evidenced by 40+ regulatory approvals across the portfolio) means they are not passive capital.
The firm's track record of supporting companies through FDA approvals and all the way to strategic M&A exits makes them a particularly attractive partner for medtech founders who need a lead investor with genuine exit-pathway experience. If you are pre-commercial with strong clinical data and a clear strategic acquirer landscape — exactly the profile Lumira's first Fund V investment fits — now is the time to be in conversation with the firm.
Fund Momentum Take
Lumira Fund V is the most credible dedicated healthcare VC raise in Canada in years, and arguably one of the strongest in North America for the sector. The combination of a structured leadership succession, fresh capital, and a macro environment that genuinely favors specialist healthcare operators creates a rare alignment of conditions. We expect Fund V to be fully invested within 4-5 years, with exits potentially accelerating as the 2027-2030 Big Pharma M&A window opens wider.
The one risk worth naming: Canada's life sciences commercialization ecosystem, while improved, still lags the US on regulatory agency speed and strategic acquirer proximity. Lumira's Boston office addresses some of this, but the fund's Canadian founders will still face a longer path to US commercialization than US-based peers. Brunk's point about capital efficiency being a core discipline is well-taken — in healthcare, capital-efficient companies with Canadian origins tend to punch above their weight in M&A outcomes precisely because they've been forced to be disciplined.
Our bet: Gerry Brunk is one of the most underrated healthcare VC operators on the continent. Fund V will demonstrate that Canada can produce top-decile life sciences returns without requiring founders to leave. Watch this one closely.
Frequently Asked Questions
What is Lumira Ventures Fund V's target size?
The fund is targeting a final size of US$200 million (C$275 million). The first close was announced in April 2026.
What is Lumira Ventures' investment focus?
Lumira invests in biotechnology and medical technology (medtech) companies across North America, with particular emphasis on secondary markets outside the traditional coastal VC hubs. They take a multi-stage approach from early to growth stage.
Who are the key GPs at Lumira Ventures?
Gerry Brunk was appointed Managing Partner in conjunction with Fund V's first close. Co-founder Peter van der Velden has transitioned to Executive Chairman. The firm also has investment professionals across Toronto, Montreal, Vancouver, and Boston.
What is Lumira Ventures' track record?
Across its history, Lumira-backed companies have delivered more than 25 exits, 40+ regulatory approvals, touched 15 million patients globally, and generated over US$100 billion in cumulative revenue. Since 2024, the firm has exited 7 companies at a cumulative value exceeding US$8 billion.
Has Fund V already made any investments?
Yes. The fund completed its first investment alongside the first close: a US$52 million Series B financing for an undisclosed pre-commercial-stage medical device company.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.